GLP-1 & Incretin Science

Why Weight Loss Can Restore Ovulation

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Obesity and insulin resistance disrupt ovulatory function, and polycystic ovary syndrome is the clearest case. Reducing weight and improving insulin sensitivity can restore ovulation. Salamun and colleagues reported liraglutide increasing IVF pregnancy rates in obese PCOS women with poor response to first-line treatment.

Key facts

Mechanism
Improved insulin sensitivity, weight reduction
Population most affected
PCOS
Pilot randomised study
Salamun 2018 (PMID 29703793)
Journal
Eur J Endocrinol, July 2018
Compound studied
Liraglutide
Setting
IVF, poor response to first-line treatment

Why insulin resistance disrupts ovulation

High circulating insulin acts on the ovary and alters steroid production, raising androgen output and disturbing the hormonal sequence that drives follicle maturation and release. It also lowers sex hormone-binding globulin, which raises free androgen further. The result is disrupted ovulatory cycling, and it is a hormonal consequence of the metabolic state rather than a primary ovarian defect.

Why PCOS is the clearest case

Polycystic ovary syndrome couples reproductive and metabolic disturbance in the same condition: irregular or absent ovulation alongside insulin resistance in a large proportion of those affected. That coupling is why an intervention acting on the metabolic side can change the reproductive side, and why this population appears repeatedly in the literature.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What the 2018 study examined

Salamun and colleagues published a pilot randomised study in the European Journal of Endocrinology examining liraglutide and IVF pregnancy rates in obese women with PCOS who had responded poorly to first-line reproductive treatment. A pilot randomised study is early-stage evidence in a defined and difficult population, not a general statement about fertility.

Why the effect is not attributable to the drug alone

The same attribution problem that runs through this entire class. Weight loss itself improves ovulatory function and has done so long before these compounds existed, through diet and surgery. Whether an incretin does anything beyond causing the weight loss is a separate question, and one this design cannot separate.

Why this matters even to people not seeking pregnancy

Because a return of ovulation is a return of fertility whether or not it was wanted. Someone whose cycles were irregular or absent may have been relying on that as a practical matter. Restoring ovulation changes that circumstance without any announcement, which is the substance of the convergence described in the companion article on this site.

What this concerns

Licensed medicines studied in registered trials under clinical supervision. Nothing supplied on this site is a GLP-1 receptor agonist, affects fertility, or has any place in reproductive care. These findings describe medicines, and decisions about fertility belong with a clinician.

Frequently asked questions

What did the 2018 study find?

It was a pilot randomised study of liraglutide and IVF pregnancy rates in obese PCOS women with poor response to first-line treatment. It is early-stage evidence in a specific population.

Is the effect from the drug or the weight loss?

Not separable. Weight loss alone improves ovulatory function, and the two occur together in the same participants.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.